Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus CAPOX in unresectable colorectal liver metastases
NCT06848842Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in colorectal cancer (CRC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Sep 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06848842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848842.